Rhythm Pharmaceuticals And RareStone Ltd. Announce Exclusive Licensing Agreement For Development And Commercialization Of IMCIVREE In China; Rhythm To Receive $12M Upfront In Cash And Equity, Up To $63.5M In Milestones

by | Dec 6, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.